Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S201000
Reexamination Certificate
active
07119106
ABSTRACT:
Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafuoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3 -methylpiperidin-3-yl)-4-aminoisoindoline.
REFERENCES:
patent: 4590189 (1986-05-01), Hiraga et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4849441 (1989-07-01), Okazaki et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5463063 (1995-10-01), Muller
patent: 5502066 (1996-03-01), Heinemann et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6228879 (2001-05-01), Green et al.
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6500845 (2002-12-01), Boehlke et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0127545 (2004-07-01), D'Amato
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 0 688 771 (1995-12-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 03/086373 (2003-10-01), None
De, A. et al. : Possible antineoplastic agents, Indian J. Chem. vol. 16 B, pp. 510-512, 1978.
Niwayama et al. “Potent inhibition of tumor necrosis factor alpha production . . . ” CA 125;104270 91996).
Wnendt et al. “Enantioselective inhibition of . . . ” CA 126:387 (1996).
Schmahl et al. “Stereoselective distribution of . . . ” CA 126:1148 (1996).
Bundgaard “design of prodrugs” Elsevier p. 24-25 (1985).
Baker Botts “In print-reach through claims” attoney's practice profiles new and events (2002).
Lendaris et al. “Reach through claims . . . ” Intellectual property update v. 4, No. 5, (2004).
Trilaterao project B3b, “Comparitive study on reach through claims” introduction,(2001).
U.S. Appl. No. 09/287,377, filed Apr. 7, 1999, D'Amato.
U.S. Appl. No. 09/545,654, filed Apr. 10, 2000, D'Amato.
I Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995).
Corral, L. et al., “Immunomodulation by thalidomide and thalidomide analogues”, Annals of the Rheumatic Diseases, vol. 58, Suppl. 1, pp. 1107-1113, 1999.
Miyachi, H. et al., Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor- Production-Regulating Activity, J. Med. Chem., pp. 2858-2865 (1997).
Muller, George et al., Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF- Production, Bioorganic & Medicinal Chem. Letters 9, pp. 1625-1630 (1999).
Muller, George et al., Stuctural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity, Journal of Medicinal Chemistry, vol. 39, No. 17, pp. 3238-3240(1996).
Muller, George et al., Thalidomide Analogs and PDE4 Inhibition, Bioorganic & Medicinal Chemistry Letters 8, pp. 2669-2674 (1998).
Shannon, Edward J. et al., Immunomodulatory Assays to Study Structure-Activity Relationships of Thalidomide Immunopharmacology 35, pp. 203-212 (1997).
Smith, R. L. et al., Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds, Symp. Embryopathic Act. Drugs, pp. 194-209 (1965).
Takeuchi, Yoshio et al., (R)- and (S)-3-Fluorothalidomides: Isosteric Analogues of Thalidomide, American Chemical Society, vol. 1, No. 10, pp. 1571-1573 (1999).
Udagawa, Taturo et al., Thalidomide and Analogs, Antianglogenia Agents in Cancer Therapy, pp. 263-274.
Zwingenberger, K. et al., Immunomodulation by Thalidomide: Systematic Review of the Literature and of Unpublished Observations, Journal of Inflammation, pp. 177-211 (1996).
Niwayama et al.,J. Med. Chem. 39(16):3044-45, 1996.
Schmahl et al.Arch. Toxicol. 70 (11):749-756, 1996.
Wnendt et al.Chirality8(5):390-396, 1996.
Chen Roger Shen-Chu
Muller George W.
Stirling David I.
Celgene Corporation
Chang Celia
Jones Day
LandOfFree
Pharmaceutical compositions of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702867